Imprivata
Purchase-Price Allocation
Goodwill
$9.2M
Intangibles
$9.8M
Contingent Earn-Out
$7.3M
SAILPOINT, INC. — Key Metrics
2 years of history · ending 2026-01-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-0
Book Value Per Share
$13
Free Cash Flow Per Share
$0
Cash Per Share
$1
Revenue Per Share
$2
OCF Per Share
$0
Return on Equity
-42.9%
Return on Assets
-3.6%
Return on Invested Capital
-21.3%
Debt to Equity
0.00
Current Ratio
1.32
Quick Ratio
1.32
Asset Turnover
0.14
Days Sales Outstanding
114.13
Days Payables Outstanding
5.58
R&D / Revenue
20.8%
SBC / Revenue
23.8%
Capex / Revenue
0.6%
Working Capital
$207M
Net Current Asset Value
$99M
Invested Capital
$6.85B
OCF / Net Income
-0.26
FCF / Net Income
-0.24
Accruals Ratio (Sloan)
-4.5%
Net Debt
$-358M
Net Debt / EBITDA
3.70
Interest Coverage
-12.48
Cash Coverage
2.87
Capex Coverage
11.80
Tangible Common Equity
$317M
TCE / Total Assets
4.2%
Goodwill / Total Assets
67.8%
NOPAT
$-243M
Cash ROIC
5.7%
WC / Revenue
19.4%
Capex / D&A
0.03
Reinvestment Rate
66.6%
Total Payout Ratio
0.0%
Asset Growth vs Revenue Growth
-21.8%
Stock Price (FY-end)
$16
Market Cap
$8.54B
P/S Ratio
7.97
P/B Ratio
1.25
P/TB Ratio
26.91
P/OCF Ratio
120.97
P/FCF Ratio
132.16
Enterprise Value
$8.18B
EV / Sales
7.63
EV / FCF
126.62
FCF Yield
0.8%
Shareholder Yield
-3.0%
Buyback Yield
0.0%
R&D Yield
2.6%
Capex Yield
0.1%
Shares Variation (YoY)
550.0%
Beta (5Y)
1.61
Cost of Equity
12.5%
Cost of Debt (after tax)
14.4%
52W High
$26
52W Low
$16
F-Score (Piotroski)
6.00
Z-Score (Altman)
6.81
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
SAILPOINT, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 3.10% | 3.30% | 0.80% |
| Foreign Rate Differential | -0.10% | -0.30% | — |
| Other Adjustments | -0.40% | -0.10% | 0.20% |
| R&D Tax Credits | -2.20% | -1.60% | -2.30% |
| SBC (Nondeductible) | -1.60% | -1.80% | -4.60% |
| Valuation Allowance Change | 0.00% | -6.30% | 6.50% |
| Tax Law Change | — | — | 0.00% |
| Effective Tax Rate | 22.80% | 16.10% | 17.20% |
Cash vs Accrual
| Item | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Income Tax Expense (Accrual) | −$117.0M | −$60.8M | −$55.9M |
| Income Taxes Paid (Cash) | $5.6M | $12.9M | $6.9M |
SAILPOINT, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Osirium
Purchase-Price Allocation
Goodwill
$8.3M
Intangibles
$2.4M
Deferred Tax Liability
$590.0K
Double Zero
Purchase-Price Allocation
Goodwill
$3.6M
Intangibles
$1.4M
Contingent Earn-Out
$800.0K